Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD + cyclophosphamide followed by docetaxel as neoadjuvant therapy for locally advanced breast cancer
ChiCTR1900023052Phase 4Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jun 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doxorubicin, cyclophosphamide and docetaxel in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathologic complete response rate. Started Jun 2015; status: completed.
02
Drugs
doxorubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900023052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023052.